Antibody Therapeutics for Life

Notices

Dr. Lawrence Cher at Olivia Newton-Johns Cancer Wellness & Research Center/Austin Hospital is invited to present the interim data of Tanibirumab phase IIa recurrent GBM trial at 2017 SNO (Society for Neuro Oncology) meeting in San Francisco on November 16
  • Written by Admin
  • Written date 2019-01-14 11:28:01
  • Inquire 7528

Dr. Lawrence Cher at Olivia Newton-Johns Cancer Wellness & Research Center/Austin Hospital is invited to present the interim data of Tanibirumab 

phase IIa recurrent GBM trial at 2017 SNO (Society for Neuro Oncology) meeting in San Francisco on November 16-19th, 2017.

List





Prev PharmAbcine`s ``BI(Business Incubation) Research Grant`` proposal is granted by ...
Next Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present as panelist at KoNECT-...